|Gilotrif||Tablet, film coated||20 mg/1||Oral||Boehringer Ingelheim|
|Gilotrif||Tablet, film coated||40 mg/1||Oral||Boehringer Ingelheim|
|Gilotrif||Tablet, film coated||30 mg/1||Oral||Boehringer Ingelheim|
|Giotrif||Tablet||20 mg||Oral||Boehringer Ingelheim (Canada) Ltd Ltee|
|Giotrif||Tablet||40 mg||Oral||Boehringer Ingelheim (Canada) Ltd Ltee|
|Giotrif||Tablet||30 mg||Oral||Boehringer Ingelheim (Canada) Ltd Ltee|
Afatinib is a tyrosine kinase inhibitor which is a 4-anilinoquinazoline. It is prepared has the dimaleate salt. FDA approved on July 12, 2013.
Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer
Following oral administration, time to peak plasma concentration (Tmax) is 2 to 5 hours. The geometric mean relative bioavailability of 20 mg tablets was 92% as compared to an oral solution. Food decreases Cmax and AUC relative to the fasted state.
Enzymatic metabolism of afatinib is minimal. Covalent adducts to proteins are the major circulating metabolites.
Most common adverse reactions (≥20%) are diarrhea, rash/dermatitis, acneiform, stomatitis, paronychia, dry skin, decreased appetite, pruritus.